Under the direction of the coordinating Member State referred to in Article 78(2 ) , the Member States shall coordinate their assessment of serious adverse events and device deficiencies to determine whether to modify , suspend or terminate the clinical investigation or whether to revoke the authorisation for that clinical investigation .